Cipla tops drug overcharging dues with ₹3,576 crore; J&J, Ranbaxy among top five

For more than four decades, India’s drug price regulator has been trying to recover money from pharmaceutical companies that charged patients more than the prices allowed under the law. But the latest government data shows that thousands of crores remain unpaid, with several cases stuck in courts, under recovery proceedings or pending with district authorities. As of March 2026, ₹8,530 crore in overcharging dues, including interest, remains outstanding, with Cipla alone accounting for ₹3,576 crore.

The government regulates the prices of certain medicines to prevent companies from charging patients more than the permitted amount. When a company sells a price-controlled medicine above the applicable ceiling price, it is liable to pay the excess amount to the National Pharmaceutical Pricing Authority (NPPA), along with interest under the Drug Price Control Order (DPCO).

The latest data from the Department of Pharmaceuticals shows that Cipla, Johnson & Johnson, Ranbaxy Laboratories, Sun Pharmaceutical Group and Claris Life Sciences are among the top companies with the highest outstanding dues. The cases span successive Drug Price Control Orders (DPCO), with several dating back to the 1990s and early 2000s.

Cipla has the highest outstanding dues at ₹3,576.54 crore across formulations and brands, including cases in which the company is named alongside manufacturing or marketing partners. Its liabilities are spread across several formulations, with salbutamol-based medicines accounting for ₹648.85 crore, norfloxacin-based formulations ₹541.85 crore and ciprofloxacin-based formulations ₹437.21 crore.

Among its branded medicines, Ciplox-TZ alone accounts for ₹307.27 crore in outstanding dues, including ₹189.08 crore in interest. Ciplox 500 mg tablets account for another ₹232.09 crore, while Duolin Rotacaps have outstanding dues of ₹250.82 crore. Other products include Ciplox E/E Drops, Aerocort Forte Rotacaps, Duolin Inhaler and Asthalin tablets. Most of these cases are either under litigation or pending further action.

Johnson & Johnson is second on the list, with outstanding dues of ₹658.93 crore. Its liabilities are largely concentrated in the Benadryl cough syrup range. The largest amount, ₹436.07 crore, is outstanding against Benadryl Cough Syrup 150 ml, followed by ₹196.21 crore against the 50 ml pack and ₹25.71 crore against the 450 ml pack. All three cases are listed as under process.

Ranbaxy Laboratories follows with outstanding dues of approximately ₹538.50 crore, largely linked to antibiotic formulations. Ciprofloxacin accounts for ₹321.85 crore, while ciprofloxacin-based formulations account for another ₹107.43 crore. Other products include Synsama tablets ( ₹56.55 crore), norfloxacin-based formulations ( ₹14.61 crore) and Suprimox capsules (₹ 12.27 crore). The company’s dues are spread across multiple brands and products, including those involving associated entities.

Sun Pharmaceutical Group is fourth, with outstanding dues of nearly ₹239.48 crore. Its product list includes Rosuvas 10 tablets, with dues of ₹46.11 crore; Volibo 0.3 tablets ( ₹25.84 crore) and Rosuvas 20 tablets ( ₹20.69 crore). Other formulations include Cardivas 3.125 tablets ( ₹13.21 crore), Volibo 0.2 tablets ( ₹12.99 crore) and Korandil-5 tablets (₹12.54 crore).

Claris Life Sciences rounds off the top five, with outstanding dues of ₹230.85 crore. Its liabilities are concentrated in intravenous (IV) fluid formulations. Government records show ₹171.73 crore outstanding against IV Fluid, with another ₹59.12 crore recorded in a separate entry involving Baxter India and Claris. The case is listed as under process.

The figures include interest and account for amounts already recovered. However, the recovery process remains incomplete, with several cases still under litigation, while others are pending further action or recovery. The data also reflects how claims arising from alleged overcharging under older price control regimes continue to remain on the government’s books decades later.